Recurrent squamous cell carcinoma of the skin presents a challenging situation for patients and doctors alike. When this cancer returns after initial treatment, managing it requires a thoughtful approach that considers the individual’s overall health, the location and extent of the recurrence, and the available treatment options. Understanding what treatments exist today and what promising therapies are being explored in clinical trials can help patients navigate this difficult journey with hope and informed choices.

Managing Cancer That Returns: Goals and Approaches

When squamous cell carcinoma comes back after initial treatment, the focus shifts to addressing the recurrence in a way that balances effectiveness with quality of life. The primary goals include removing or controlling the cancer, preventing further spread, managing symptoms, and helping patients maintain their daily activities as much as possible. Treatment decisions depend heavily on where the cancer has returned, how large or aggressive it appears, and the patient’s overall physical condition.^[2]

Recurrent squamous cell carcinoma of the skin is not a common occurrence, but it can be difficult to treat, especially when it affects elderly individuals who may have other health problems. The location of the recurrence matters greatly—cancer returning in the same spot where it was originally removed may require different strategies than cancer that has spread to nearby areas or even to distant parts of the body. The disease can sometimes return months or even years after the first treatment, which underscores the importance of long-term monitoring.^[2][6]

Medical teams often work together across different specialties when dealing with recurrent cases. This might include dermatologists, surgical specialists, cancer doctors who specialize in drug treatments, and radiation experts. This collaborative approach helps ensure that patients receive comprehensive care tailored to their specific situation. The treatment plan may also take into account whether the patient has a weakened immune system, a history of multiple skin cancers, or tumors located in high-risk areas like the lips, ears, or scalp.^[6][12]

Standard Treatment Options for Recurrent Disease

The backbone of treating recurrent squamous cell carcinoma remains surgical removal whenever possible. When the cancer is detected early in its return and has not spread extensively, doctors typically recommend excising the tumor with a margin of healthy tissue around it. This approach aims to ensure that all cancerous cells are removed. The type of surgery chosen depends on the tumor’s size, location, and depth.^[8]

One specialized surgical technique called Mohs micrographic surgery is often considered for recurrent tumors, particularly those on the face or other cosmetically sensitive areas. During this procedure, the surgeon removes thin layers of tissue one at a time and examines each layer under a microscope immediately. This continues until no cancer cells are visible. Mohs surgery has the advantage of preserving as much healthy tissue as possible while ensuring complete cancer removal. Studies suggest that Mohs surgery results in recurrence rates of less than 1 percent within five years, making it one of the most effective surgical options.^[5]

When surgery is not feasible—perhaps because the tumor is too large, located in a difficult area, or the patient’s health makes surgery too risky—radiation therapy may be used as an alternative. Radiation therapy uses high-energy beams to destroy cancer cells. It can be delivered externally through a machine that directs radiation to the tumor site. The treatment is typically given in multiple sessions over several weeks. Radiation may also be used after surgery to kill any remaining cancer cells that might have been left behind, reducing the chance of the cancer coming back again.^[10]

For smaller, superficial recurrences that have not penetrated deeply into the skin, less invasive treatments might be considered. These include cryosurgery, which involves freezing the cancer cells with liquid nitrogen, and electrodessication and curettage, where the tumor is scraped away and the base is burned with an electric needle. However, these methods generally have higher recurrence rates compared to surgical excision or Mohs surgery. For example, recurrence risk after cryotherapy is approximately 7.5 percent, while it rises to just under 8 percent after electrodessication and curettage, and about 10 percent after standard surgical excision.^[5][10]

When recurrent squamous cell carcinoma cannot be removed surgically due to its location or extent, or when it has spread to other parts of the body, systemic treatments become necessary. Traditionally, chemotherapy has been used in these situations. The most commonly used chemotherapy drug is cisplatin, often combined with other medications. Studies have reported high response rates with cisplatin-based regimens, but these treatments come with significant side effects.^[2][8]

Chemotherapy affects the entire body because it travels through the bloodstream. Common side effects include nausea and vomiting, fatigue, hair loss, low blood cell counts that increase infection risk, and potential damage to the kidneys (nephrotoxicity). Because many patients with recurrent squamous cell carcinoma are elderly and may have other medical conditions, the decision to use chemotherapy must be made carefully, weighing the potential benefits against these considerable side effects. The duration of chemotherapy varies depending on how well the cancer responds and how well the patient tolerates the treatment.^[2][8]

Innovative Treatments Being Tested in Clinical Trials

The landscape of treatment for advanced and recurrent squamous cell carcinoma has been evolving rapidly thanks to clinical research. One of the most promising developments involves targeted therapies that work differently from traditional chemotherapy by focusing on specific molecules involved in cancer growth.

Cetuximab is a targeted therapy that has shown considerable promise for recurrent squamous cell carcinoma. This medication is a chimeric monoclonal antibody, which means it is a laboratory-made molecule designed to attach to a specific target on cancer cells. Cetuximab targets the epidermal growth factor receptor (EGFR), a protein found on the surface of many cells. In squamous cell carcinoma, this receptor is often overactive, sending signals that encourage the cancer cells to grow and divide rapidly.^[2][8]

By blocking the EGFR, cetuximab interrupts these growth signals, which can slow or stop the cancer’s progression. Importantly, because cetuximab targets a specific protein rather than all rapidly dividing cells (like traditional chemotherapy does), it tends to cause fewer and less severe side effects. Case reports have described patients with recurrent squamous cell carcinoma who could not undergo surgery and who achieved complete resolution of their disease with cetuximab treatment while experiencing only minimal toxicity. These encouraging results have led to increased interest in using cetuximab as an alternative treatment, particularly for elderly patients with poor overall health who cannot tolerate harsh chemotherapy regimens.^[2][8]

The use of cetuximab represents part of a broader category of treatments known as immunotherapy. Unlike chemotherapy, which directly kills cancer cells, immunotherapy works by helping the body’s own immune system recognize and attack cancer cells. Over recent years, the field of immunotherapy has grown significantly, offering new hope for patients with advanced squamous cell carcinoma that has spread extensively or resisted multiple treatments.^[9]

Clinical trials are ongoing to test various immunotherapy approaches for advanced cutaneous squamous cell carcinoma (the medical term that specifies this is skin cancer, not squamous cell cancer arising in other parts of the body). These trials typically progress through different phases. Phase I trials focus primarily on determining whether a new treatment is safe and identifying the appropriate dose. Phase II trials examine whether the treatment is effective in treating the cancer and continue to monitor safety. Phase III trials compare the new treatment directly against current standard treatments to determine if it offers better results.^[9]

Beyond immunotherapy, researchers are exploring other innovative molecular therapies and combinations of treatments. Some trials investigate enzyme inhibitors that block specific proteins needed for cancer cell survival and growth. Others examine whether combining targeted therapies with radiation or surgery can improve outcomes. The advantage of many of these newer treatments is that they may work even when cancer has become resistant to traditional therapies or has recurred multiple times.^[9]

Patient eligibility for clinical trials varies depending on the specific study. Generally, trials for advanced squamous cell carcinoma look for patients whose cancer has spread locally in a way that makes it inoperable, or whose cancer has metastasized (spread) to distant parts of the body. Some trials specifically seek patients who have tried standard treatments without success. Clinical trials for these therapies are conducted in various locations, including the United States, Europe, and other regions, though specific trial locations depend on the research institution conducting the study.^[9]

Most common treatment methods

• Surgical Treatments
  • Surgical excision involves removing the tumor along with a margin of healthy tissue, with recurrence risk of approximately 10 percent within five years
  • Mohs micrographic surgery removes cancer in thin layers that are examined microscopically during the procedure, resulting in less than 1 percent recurrence rate
  • Electrodessication and curettage scrapes away the tumor and burns the base with an electric needle, with recurrence risk just under 8 percent
  • Cryosurgery freezes cancer cells with liquid nitrogen, carrying approximately 7.5 percent recurrence risk
• Radiation Therapy
  • External beam radiation directs high-energy beams to destroy cancer cells when surgery is not feasible
  • Treatment typically involves multiple sessions over several weeks
  • May be used after surgery to eliminate remaining cancer cells and reduce recurrence risk
• Chemotherapy
  • Cisplatin-based chemotherapy forms the backbone of systemic treatment for advanced or metastatic disease
  • Works throughout the body via the bloodstream to kill cancer cells
  • Common side effects include nausea, vomiting, low blood counts, and kidney toxicity
  • Particularly challenging for elderly patients with multiple health conditions
• Targeted Therapy
  • Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR)
  • Works by interrupting growth signals that encourage cancer cell division
  • Case reports show complete disease resolution with minimal toxicity in elderly patients
  • Causes fewer and less severe side effects compared to traditional chemotherapy
• Immunotherapy
  • Helps the body’s immune system recognize and attack cancer cells
  • Increasingly used for advanced cutaneous squamous cell carcinoma
  • Offers new options for patients whose cancer has spread extensively or resisted other treatments
  • Being tested in various clinical trial phases for safety and effectiveness

Long-Term Monitoring and Prevention of Further Recurrences

After treatment for recurrent squamous cell carcinoma, establishing a careful follow-up schedule becomes critically important. The majority of recurrences that happen again—between 70 and 80 percent—occur within the first two years following treatment. This means that frequent medical appointments and examinations during this period are essential for catching any new problems early when they are most treatable.^[20]

Follow-up care typically includes regular full-body skin examinations by a dermatologist. The frequency of these visits depends on the stage and risk factors of the original cancer. Patients are also taught to perform monthly self-examinations at home, checking their entire body for any new growths, sores that don’t heal, or changes in existing spots. Early detection through these examinations can make a significant difference in treatment outcomes.^[6][12]

For patients who had high-risk squamous cell carcinoma or cancer that had spread to lymph nodes, follow-up care may also include regular examination of the lymph nodes. These small, bean-shaped structures are part of the immune system and are often the first place cancer spreads beyond the original site. Patients can learn to check their own lymph nodes using gentle circular motions with their fingertips, feeling for any unusual lumps or swelling, particularly in the head, neck, and areas near where the original cancer was located.^[20]

Sun protection becomes even more crucial after a diagnosis of squamous cell carcinoma. The same ultraviolet radiation from the sun or tanning beds that caused the original cancer remains a threat. Patients should wear broad-spectrum sunscreen with SPF 30 or higher every day, even on cloudy days, and reapply it every two hours when outdoors. Protective clothing, wide-brimmed hats, and seeking shade during peak sun hours (typically 10 AM to 4 PM) all help reduce further UV damage. Avoiding tanning beds entirely is strongly recommended, as they are a significant source of harmful UV radiation.^[6][12][17]